On May 9, 2025, Soligenix, Inc. (SNGX) announced financial results for the first quarter of 2025 and provided a business update. Enrollment continues in the confirmatory Phase 3 trial of HyBryte in patients with cutaneous T cell lymphoma (CTCL). We anticipate topline results from this study in 2026. The company recently announced interim results from the ongoing investigator-initiated study of extended therapy HyBryte (up to 54 weeks) that showed a 75% response rate and three complete responses. We anticipate topline results from the ongoing Phase 2 clinical trials of SGX945 (dusquetide) in Behcet's disease and SGX302 (synthetic hypericin) in mild-to-moderate psoriasis in the second half of 2025.
